iVeena develops ocular drug products that eliminate the need for eye drop application and painful injections.
iVeena has raised $3.0M in total funding. The most recent round was Series B. The last funding was announced in February 2025.
iVeena's investors include National Science Foundation, Park City Angels, Mountain Pacific Partners, PC Squared, LLC, Technology Venture Corporation.
iVeena is headquartered in Salt Lake City, United States.
iVeena develops ocular drug products that eliminate the need for eye drop application and painful injections.
iVeena is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"iVeena — Funding & Investors." VCBacked, February 5, 2025, https://www.vcbacked.co/company/iveena. Accessed July 21, 2026.
VCBacked. (2025). iVeena — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/iveena
{{cite web |title=iVeena — Funding & Investors |url=https://www.vcbacked.co/company/iveena |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated